Horizon Pharma Inc. (HZNP) Given a $26.00 Price Target by Goldman Sachs Group Inc. Analysts
Horizon Pharma Inc. (NASDAQ:HZNP) received a $26.00 price objective from equities research analysts at Goldman Sachs Group Inc. in a research report issued to clients and investors on Wednesday. The brokerage currently has a a “buy” rating on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s price objective would indicate a potential upside of 47.14% from the stock’s current price.
HZNP has been the subject of several other reports. Guggenheim reissued a “buy” rating and issued a $30.00 price objective on shares of Horizon Pharma in a research note on Tuesday, August 23rd. Cowen and Company reaffirmed an “outperform” rating and set a $42.00 price target on shares of Horizon Pharma in a research report on Monday, September 12th. Vetr raised Horizon Pharma from a “buy” rating to a “strong-buy” rating in a research report on Monday, October 3rd. Mizuho increased their price target on Horizon Pharma from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Tuesday, September 13th. Finally, Morgan Stanley reaffirmed a “hold” rating and set a $24.00 price target on shares of Horizon Pharma in a research report on Wednesday, September 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $29.92.
Horizon Pharma (NASDAQ:HZNP) traded up 1.41% during mid-day trading on Wednesday, hitting $17.92. The stock had a trading volume of 2,472,665 shares. The company’s market cap is $2.88 billion. Horizon Pharma has a 12 month low of $12.86 and a 12 month high of $23.70. The firm’s 50-day moving average is $18.79 and its 200 day moving average is $17.86.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/horizon-pharma-inc-hznp-given-a-26-00-price-target-by-goldman-sachs-group-inc-analysts-2.html
Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.50 by $0.12. The firm earned $257.40 million during the quarter, compared to the consensus estimate of $235.43 million. Horizon Pharma had a positive return on equity of 23.46% and a negative net margin of 0.34%. The company’s quarterly revenue was up 48.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.39 earnings per share. Equities analysts anticipate that Horizon Pharma will post $2.15 EPS for the current fiscal year.
In related news, EVP Jeffrey W. Sherman sold 2,900 shares of Horizon Pharma stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total transaction of $58,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.10% of the stock is owned by insiders.
A number of large investors have recently bought and sold shares of HZNP. Canada Pension Plan Investment Board acquired a new stake in Horizon Pharma during the first quarter valued at about $114,000. Societe Generale acquired a new stake in Horizon Pharma during the second quarter valued at about $117,000. SG Americas Securities LLC acquired a new stake in Horizon Pharma during the second quarter valued at about $117,000. Nuveen Asset Management LLC acquired a new stake in Horizon Pharma during the second quarter valued at about $176,000. Finally, Profund Advisors LLC acquired a new stake in Horizon Pharma during the second quarter valued at about $194,000. 85.25% of the stock is owned by institutional investors.
Horizon Pharma Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.